Dossier assessment
Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more DMARDs
First-time therapy with bDMARDs or tsDMARDs indicated: in combination with MTX, hint of minor added benefit. Other constellations: added benefit not proven.
Project details
- Project no.
- A20-90
- Commission
- Commission awarded on 15.10.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed